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Perspectives
Nanomedicine formulations for
combination therapies
N
anomedicine formulations are nanometer-sized
carrier materials designed for improving the
biodistribution of systemically applied (chemo-)
therapeutic drugs. Clinically relevant examples of nano-
medicine formulations are liposomes, polymers and
micelles. By delivering pharmacologically active agents
more selectively to pathological sites (site-specific drug
delivery) and/or by guiding them away from potentially
endangered healthy tissues (site-avoidance drug delivery),
nanomedicine formulations aim to improve the balance
between the efficacy and the toxicity of therapeutic
interventions (1).
For obvious reasons, the majority of efforts in the
nanomedicine field have focused on cancer, and a
significant amount of preclinical evidence has been
obtained showing that both passively and actively
targeted carrier materials are able to improve the
tumor-directed delivery of low molecular weight che-
motherapeutic drugs. As a result of this, the antitumor
efficacy of the conjugated or entrapped chemotherapeutic
drug can often be substantially improved, while its
toxicity can be attenuated.
Clinically, however  i.e. in patients instead of in
animal models  nanomedicine formulations have thus
far largely failed to improve the efficacy of chemother-
apeutic interventions, in spite of clear evidence for
prolonged circulation times and increased tumor con-
centrations. The primary justification for approving the
well-known liposomal doxorubicin formulations Doxil
and Myocet (i.e. PEGylated and unPEGylated liposomal
doxorubicin, respectively), for instance, has been their
ability to attenuate drug-related toxicity (i.e. cardiomyo-
pathy, bone marrow depression, alopecia and nausea)
rather than to enhance antitumor efficacy. This can be
exemplified by taking the results of a phase III head-to-
head comparison of free doxorubicin versus Myocet in
patients with metastatic breast cancer into account, in
which similar response rates (26%) and progression-free
survival times (4 months) were found but in which the
incidence of cardiac events (29 vs. 13%) and of congestive
heart failure (8 vs. 2%) was significantly lower for the
liposomal agent (1, and references therein).
Also for Doxil, significant reductions in cardiomyo-
pathy were observed as compared to the free drug, while
its response rates, its progression-free survival times and
its overall survival times were comparable. Only in certain
specific cases, e.g. in patients suffering from AIDS-related
Kaposi Sarcomas, which are characterized by a dense and
highly permeable vasculature, Doxil turned out to be able
to improve both the efficacy and the toxicity of the
intervention: as compared to the formerly standard
combination regimen ABV (i.e. adriamycin [doxorubi-
cin], bleomycin, and vincristine), which produced a
partial response in 31 out of 125 patients (RR25%),
Doxil achieved 1 complete response and 60 partial
responses (RR46%) (1, and references therein).
Similar findings have been reported for polymer ther-
apeutics. PK1, for instance  i.e. poly[N-(2-hydroxypro-
pyl)methacrylamide]-GlyPheLeuGly-doxorubicin; the
first tumor-targeted polymeric prodrug to enter clinical
trials was also found to be equally effective and less toxic
than free doxorubicin. Aswas the case for Myocet and for
Doxil, as opposed to highly promising results observed in
animal models, in patients, PK1 was only found to be able
to improve the therapeutic index of doxorubicin by
attenuating its toxicity. This can be exemplified by taking
into account that the maximum tolerated dose determined
for PK1 was more than five times higher than that of free
doxorubicin(320vs.60mg/m
2,respectively),butthatclear
responses were only observed in 4 out of 36 patients (i.e.
two partial and two minor responses; in patientswith non-
small cell lung cancer, colorectal cancer, and doxorubicin-
resistant breast cancer) (1, and references therein).
To overcome this shortcoming and to broaden the
clinical applicability of tumor-targeted nanomedicines,
we (and others) have in the past 5 years developed several
concepts for using nanomedicine formulations to improve
the efficacy of combined modality anticancer therapy (2).
Convincing and clinically highly relevant evidence has for
instance been obtained showing that nanomedicine for-
mulations are highly useful for improving the efficacy of
radiochemotherapy and of chemotherapy combinations.
Regarding the former (i.e. radiochemotherapy), we
have for instance been able to show that local external
beam radiotherapy and polymeric nanomedicines inter-
act synergistically, with radiotherapy improving the
tumor accumulation of HPMA copolymers, and with
the copolymers improving both the efficacy and the
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(page number not for citation purpose)tolerability of radiochemotherapy. Using magnetic reso-
nance imaging and g-scintigraphy, we demonstrated in
three different tumor models that pretreating tumors with
radiotherapy increases their tumor accumulation by
25%100%, depending on polymer size and on the tumor
model used (3). These findings were explained by taking
into account that radiotherapy increases the production
of the permeability-enhancing growth factors VEGF
(vascular endothelial growth factor) and FGF (fibroblast
growth factor), that it induces endothelial cell apoptosis,
that it reduces the cell density in tumors, and that it
lowers the interstitial fluid pressure. In addition to this,
reasoning that (I) the temporal and spatial interaction
between i.v. applied weekly chemotherapy and clinically
relevant daily radiotherapy is suboptimal, and that (II)
long-circulating and passively tumor-targeted nanomedi-
cines are able to improve the temporal and spatial
parameters of this interaction (Fig. 1A, B), we have
shown that HPMA copolymers are able to improve both
the efficacy and the toxicity of clinically relevant regimens
of radiochemotherapy (4). Both doxorubicin- and gemci-
tabine-containing copolymers were used for this purpose,
and growth inhibition was achieved in an aggressively
growing and radio- and chemo-resistant tumor model.
These findings are in line with preclinical studies in which
Doxil was combined with radiotherapy (5), as well as
with the results of a phase I trial in which 12 patients with
localized esophageal and gastric cancer were treated
with the combination of poly(l-glutamic acid)-bound
paclitaxel (Xyotax) and fractionated radiotherapy, and
in which four complete responses and an additional seven
partial responses (with reductions in tumor size of more
than 50%) were achieved (6). Together, these insights
convincingly show that ‘carrier-based radiotherapy’ holds
significant potential for improving the treatment of
advanced solid malignancies.
Regarding the latter (i.e. chemotherapy combinations),
following up on the pioneering efforts by Vicent and
colleagues (7), we have recently for the first time provided
in vivo evidence showing that passively tumor-targeted
polymeric drug carriers can be used to deliver two
different drugs to tumors simultaneously. Both doxor-
ubicin and gemcitabine were hereto co-conjugated to the
same HPMA copolymer, and it was shown that this
formulation  which we termed P-Gem-Dox  circulated
for prolonged periods of time, that it localized to tumors
both effectively and selectively, and that it increased the
efficacy of the combination of doxorubicin plus gemcita-
bine without increasing its toxicity (8). In addition to this
and in line with the proposed concept (Fig. 1C, D), it was
found that P-Gem-Dox more effectively induced apop-
tosis and reduced angiogenesis than did all relevant
control regimens. These findings are in line with the
results recently reported by Segal and colleagues, who co-
conjugated the antiangiogenic agents aminobisphospho-
nate alendronate and TNP-470 to a single HPMA
copolymer (9), as well as with those published by Mayer
and coworkers, who co-encapsulated optimal (ratio-
metric) ratios of doxorubicin and vincristine, of irinote-
can and floxuridine, and of daunorubicin and cytarabine
Fig. 1. Nanomedicine formulations hold signiﬁcant potential for improving the efﬁcacy of combined modality anticancer
therapy. AB: By improving the temporal and spatial interaction between i.v. applied weekly chemotherapy (red needle) and
clinically relevant daily radiotherapy (yellow arrow), long-circulating and passively tumor-targeted nanomedicines increase the
therapeutic index of radiochemotherapy. CD: By simultaneously and more selectively delivering multiple chemotherapeutic
agents to and into tumor cells, nanomedicine formulations lower the apoptosis threshold and thereby improve the efﬁcacy of
chemotherapy combinations.
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potential of the latter two formulations in clinical trials
(10).
Collectively, the above insights and advances convin-
cingly demonstrate that nanometer-sized carrier materials
hold significant potential for improving the efficacy of
combined modality anticancer therapy. Consequently,
they strongly suggest that along with developing novel
and ever more advanced nanomedicine formulations,
significant efforts should also be invested in establishing
novel and more optimal combination regimens, in order
to more optimally exploit the beneficial biodistribution
and the advantageous efficacy-to-toxicity ratio of tumor-
targeted nanomedicines.
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